DynaMed vs OpenEvidence
Subscription against advertising, and that is the honest frame for this comparison rather than a feature contest. DynaMed is a curated corpus built under a stated seven step methodology with a named editorial team, funded by subscriptions, with its generative layer bounded to its own content and labelled as generative. OpenEvidence is free to verified United States clinicians and paid for by pharmaceutical and device advertising, with a corpus reaching current primary literature through named partnerships with the New England Journal of Medicine, JAMA and Cochrane. On evidence OpenEvidence is unexpectedly ahead: a systematic review identified eleven independent studies evaluating it between 2024 and 2026, which is more external scrutiny than any incumbent here has attracted. On the question of whether a commercial relationship can sit next to a clinical answer, DynaMed has nothing to explain and OpenEvidence has a published policy you should read.
- The corpus is bounded and the vendor says so: a retrieval augmented framework over its own DynaMed, DynaMedex and Dynamic Health content, with generative output labelled as generative and a published principle limiting generative use in user facing applications.
- An Epic App Orchard marketplace listing from June 2021, which is a reviewed integration credential rather than a partnership claim, plus institutional single sign on and multi organisation affiliation for one clinician.
- No advertising anywhere in the product. Content is funded by subscription, so nothing in the answer path carries a commercial relationship with a manufacturer whose product might be the answer.
- The independent literature is deeper than for anything else in this category and the vendor did not commission it: a systematic review following PRISMA identified eleven studies published between 2024 and 2026 evaluating this product.
- The corpus reaches current primary literature through named partnerships with the New England Journal of Medicine, JAMA and its eleven specialty journals, and Cochrane Systematic Reviews, rather than through a publisher's own back catalogue.
- It is free to verified United States clinicians, with web and native mobile applications and enterprise deployment embedded in Epic, documented at Mount Sinai across seven hospitals.
Side by Side
| Axis | D DynaMed |
O OpenEvidence |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is monetised through pharmaceutical and medical device advertising presented alongside clinical answers, which is a structural conflict of interest that no amount of policy removes. The company publishes an advertising policy governing it, which is more than most advertising funded clinical products offer, and a buyer should read that policy rather than take the disclosure on trust.
DynaMed publishes no security attestation, trust centre, penetration testing cadence or vulnerability disclosure programme across two retrieval passes, and its HIPAA position is asserted rather than evidenced. Neither vendor publishes a bias evaluation, subgroup analysis or error taxonomy for its generative layer.